Literature DB >> 10080909

Thrombopoietin signal transduction: studies from cell lines and primary cells.

J G Drachman1, P Rojnuckarin, K Kaushansky.   

Abstract

Thrombopoietin (TPO) and its receptor Mpl support all of the developmental step necessary for megakaryocytopoiesis. In the past few years, the signaling pathways utilized by this member of the cytokine receptor family have been extensively studied, especially JAK/STAT, Ras/MAP kinase, Shc, and other adapter molecules. Many if not most of the secondary signaling pathways activated by thrombopoietin have also been identified upon binding of other hematopoietic growth factors to their cognate receptors, making the study of Mpl signaling representative of the field in general. However, identifying unique molecules or combinations of signals that direct megakaryocyte development has been an elusive goal and has led some investigators to conclude that there is little specificity during Mpl signal transduction. In this article we review the data regarding Mpl signaling with particular attention to the methods employed and critical interpretation of the data generated. Future studies will have to focus on primary bone marrow cells and intact animal models rather than transformed cell lines. Furthermore, it is likely that a comprehensive, integrative analysis of the many pathways activated by ligand binding will be necessary to understand the physiology of cytokine signaling. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080909     DOI: 10.1006/meth.1998.0734

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  9 in total

Review 1.  The end is just the beginning: megakaryocyte apoptosis and platelet release.

Authors:  J Li; D J Kuter
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

2.  Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo.

Authors:  S M Luoh; E Stefanich; G Solar; H Steinmetz; T Lipari; T I Pestina; C W Jackson; F J de Sauvage
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  A critical function for B-Raf at multiple stages of myelopoiesis.

Authors:  Tamihiro Kamata; Jing Kang; Tzong-Hae Lee; Leszek Wojnowski; Catrin A Pritchard; Andrew D Leavitt
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

4.  Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes.

Authors:  Zhi-Jian Liu; Joseph Italiano; Francisca Ferrer-Marin; Ravi Gutti; Matthew Bailey; Brandon Poterjoy; Lisa Rimsza; Martha Sola-Visner
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

5.  An ENU-induced recessive mutation in Mpl leads to thrombocytopenia with overdominance.

Authors:  E Ricky Chan; Heather Lavender; Geqiang Li; Peter Haviernik; Kevin D Bunting; Mark D Adams
Journal:  Exp Hematol       Date:  2008-12-06       Impact factor: 3.084

6.  SNARE-dependent glutamate release in megakaryocytes.

Authors:  Catherine J Thompson; Tatjana Schilling; Martin R Howard; Paul G Genever
Journal:  Exp Hematol       Date:  2010-03-27       Impact factor: 3.084

7.  Megakaryocyte polyploidy is inhibited by lysyl oxidase propeptide.

Authors:  Alexia Eliades; Nikolaos Papadantonakis; Shinobu Matsuura; Rongjuan Mi; Manish V Bais; Philip Trackman; Katya Ravid
Journal:  Cell Cycle       Date:  2013-03-21       Impact factor: 4.534

Review 8.  Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.

Authors:  Isabelle Plo; Christine Bellanné-Chantelot; Matthieu Mosca; Stefania Mazzi; Caroline Marty; William Vainchenker
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-12       Impact factor: 5.555

9.  Critical roles for the phosphatidylinositide 3-kinase isoforms p110β and p110γ in thrombopoietin-mediated priming of platelet function.

Authors:  Samantha F Moore; Nina R Smith; Thomas A Blair; Tom N Durrant; Ingeborg Hers
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.